The Latest Breaking News from AstraZeneca

City Voices: Taken together, London’s top flight mightn’t look so appealing. But that doesn’t mean that all UK stocks should be written off.

The biotech industry’s growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more.

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhere

AstraZeneca shareholders approve 2024 pay policy, showing confidence in CEO Soriot's leadership and company's future growth.

Third of voters reject Pascal Soriot’s deal but some say it is deserved as he had been ‘massively underpaid’

A new pay deal for AstraZeneca boss Pascal Soriot and the fallout from yesterday’s US inflation shock are among areas of focus for London traders.

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

AstraZeneca said Tuesday is would acquire Fusion Pharmaceuticals for $2 billion upfront. The biotech stock nearly doubled.

Britain’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatments

Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier